NEW YORK (GenomeWeb) – Taconic Biosciences has signed a license agreement with ERS Genomics to use ERS' CRISPR-Cas9 technology to generate unique murine models.
Under the agreement, Taconic receives a worldwide, non-exclusive license to CRISPR-Cas9 intellectual property often referred to as the UC Berkeley patent. ERS founder Emmanuelle Charpentier is a co-inventor of the technology.
Taconic said that the agreement complements its CRISPR service platform, and adds to its existing license with the Broad Institute. Holding licenses with both groups enables Taconic to use the technology in all cell types and in both rat and mouse species, the company noted.
Based in Hudson, NY, Taconic provides gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR-Cas9, pronuclear injection, and homologous recombination technologies.